
Sign up to save your podcasts
Or


All eyes are on the Supreme Court this week, as the temporary stay in the Texas mifepristone case expires. Andy speaks with Fatima Goss Graves from the National Women’s Law Center about the confusing rulings and what she expects the justices to do. Former FDA Commissioner Josh Sharfstein also joins to explain the dangerous precedent this case could set for FDA-approved drugs and drug development.
Keep up with Andy on Post and Twitter @ASlavitt.
Follow Fatima Goss Graves and Joshua Sharfstein on Twitter @FGossGraves and @drJoshS.
Joining Lemonada Premium is a great way to support our show and get bonus content. Subscribe today at bit.ly/lemonadapremium.
Support the show by checking out our sponsors!
Check out these resources from today’s episode:
Stay up to date with us on Twitter, Facebook, and Instagram at @LemonadaMedia.
For additional resources, information, and a transcript of the episode, visit lemonadamedia.com/show/inthebubble.
See omnystudio.com/listener for privacy information.
By Lemonada Media4.6
34723,472 ratings
All eyes are on the Supreme Court this week, as the temporary stay in the Texas mifepristone case expires. Andy speaks with Fatima Goss Graves from the National Women’s Law Center about the confusing rulings and what she expects the justices to do. Former FDA Commissioner Josh Sharfstein also joins to explain the dangerous precedent this case could set for FDA-approved drugs and drug development.
Keep up with Andy on Post and Twitter @ASlavitt.
Follow Fatima Goss Graves and Joshua Sharfstein on Twitter @FGossGraves and @drJoshS.
Joining Lemonada Premium is a great way to support our show and get bonus content. Subscribe today at bit.ly/lemonadapremium.
Support the show by checking out our sponsors!
Check out these resources from today’s episode:
Stay up to date with us on Twitter, Facebook, and Instagram at @LemonadaMedia.
For additional resources, information, and a transcript of the episode, visit lemonadamedia.com/show/inthebubble.
See omnystudio.com/listener for privacy information.

37,098 Listeners

3,531 Listeners

87,226 Listeners

32,316 Listeners

9,478 Listeners

2,855 Listeners

12,525 Listeners

8,543 Listeners

320 Listeners

5,125 Listeners

759 Listeners

599 Listeners

15,995 Listeners

10,520 Listeners

853 Listeners

3,473 Listeners

387 Listeners

243 Listeners

10,611 Listeners

88 Listeners

120 Listeners

1,893 Listeners

449 Listeners

7,090 Listeners

1,186 Listeners

6,316 Listeners

617 Listeners

87 Listeners

467 Listeners

46 Listeners

151 Listeners

77 Listeners

22 Listeners

4,435 Listeners